BLUE BELL, Pa., June 9, 2011 /PRNewswire/ — Inovio
Pharmaceuticals, Inc. (NYSE Amex:
INO), a leader in the development of therapeutic and preventive
vaccines against cancers and infectious diseases, announced today
that its majority-owned subsidiary, VGX Animal Health, Inc, will
present at VetHealth Global 2011, an international animal health
and nutrition business conference being held June 14-17, 2011, in
Charlottetown, Prince Edward Island, Canada. Douglas Kern,
DVM, VGX Animal Health’s Vice President of Business Development,
will make the presentation.
Dr. Kern will highlight VGX Animal Health’s focus on companion
animal products including their development of VAH-1000 for
cancer-associated anemia in dogs and, VAH-1050C for chronic renal
failure in cats and VAH-1050D for chronic renal failure in dogs.
Dr. Kern will also discuss VGX Animal Health’s recent work with
VAH-5000D, a very promising “universal” DNA cancer vaccine
candidate for use in dogs.
Dr. Kern will speak at the conference during:Session VInnovation
Spotlight: Early Stage Company PresentationsPresentation: VGX
Animal Health, GHRH & TERT Programs; Overview and Investment
PotentialThursday, June 16, 20118:30AM – 10AMDouglas Kern,
DVM, Vice President of Business Development, VGX Animal HealthAbout
VGX Animal Health
VGX Animal Health is developing DNA-based therapies for
companion and food animals utilizing proprietary plasmid-based DNA
delivery and expression technology to optimize an animal’s natural
biological and immunological potential. The company is a
majority-owned subsidiary of Inovio Pharmaceuticals, Inc.
About Inovio Pharmaceuticals, Inc.
Inovio is developing a new generation of vaccines, called DNA
vaccines, to treat and prevent cancers and infectious diseases. Its
SynCon™ vaccines are designed to provide broad cross-strain